```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  JAN 27   Source of Registration (SR) information in REGISTRY updated
                   and searchable
 NEWS  4  JAN 27   A new search aid, the Company Name Thesaurus, available in
                   CA/CAplus
 NEWS  5  FEB 05   German (DE) application and patent publication number format
                   changes
 NEWS  6  MAR 03   MEDLINE and LMEDLINE reloaded
 NEWS  7  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 03   FRANCEPAT now available on STN
 NEWS  9  MAR 29   Pharmaceutical Substances (PS) now available on STN
 NEWS 10  MAR 29   WPIFV now available on STN
 NEWS 11  MAR 29   New monthly current-awareness alert (SDI) frequency in RAPRA
 NEWS 12  APR 26   PROMT: New display field available
 NEWS 13  APR 26   IFIPAT/IFIUDB/IFICDB: New super search and display field
                   available
 NEWS 14  APR 26   LITALERT now available on STN
 NEWS 15  APR 27   NLDB: New search and display fields available
 NEWS 16  May 10   PROUSDDR now available on STN
 NEWS 17  May 19   PROUSDDR: One FREE connect hour, per account, in both May
                   and June 2004
 NEWS 18  May 12   EXTEND option available in structure searching
 NEWS 19  May 12   Polymer links for the POLYLINK command completed in REGISTRY
 NEWS 20  May 17   FRFULL now available on STN
 NEWS 21  May 27   STN User Update to be held June 7 and June 8 at the SLA 2004
                   Conference
 NEWS 22  May 27   New UPM (Update Code Maximum) field for more efficient patent
                   SDIs in CAplus
 NEWS 23  May 27   CAplus super roles and document types searchable in REGISTRY
 NEWS 24  May 27   Explore APOLLIT with free connect time in June 2004

 NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:51:50 ON 04 JUN 2004
```

```
=> file polymers
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'APOLLIT' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (c) 2004 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (c) 2004 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 09:52:02 ON 04 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (c) 2004 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 09:52:02 ON 04 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'PASCAL' ENTERED AT 09:52:02 ON 04 JUN 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 09:52:02 ON 04 JUN 2004
Copyright (C) 2004 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (C) 2004 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'TEXTILETECH' ENTERED AT 09:52:02 ON 04 JUN 2004
COPYRIGHT (C) 2004 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 09:52:02 ON 04 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:52:02 ON 04 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 09:52:02 ON 04 JUN 2004
```

FILE 'WPINDEX' ENTERED AT 09:52:02 ON 04 JUN 2004

FILE 'WTEXTILES' ENTERED AT 09:52:02 ON 04 JUN 2004


```
=> s pyrimidine(w)nucleotide
L1         6860 PYRIMIDINE(W) NUCLEOTIDE

=> l1 and side(w)effect
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 and side(w)effect
  15 FILES SEARCHED...
L2          810 L1 AND SIDE(W) EFFECT

=> s l3 and chemotherapy
L3 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l2 and chemotherapy
   3 FILES SEARCHED...
   5 FILES SEARCHED...
L3          119 L2 AND CHEMOTHERAPY

=> s l3 and treat?
  15 FILES SEARCHED...
L4          117 L3 AND TREAT?

=> s l1 and precursor
L5          873 L1 AND PRECURSOR

=> s l5 and side(w)effect
  17 FILES SEARCHED...
L6          228 L5 AND SIDE(W) EFFECT

=> s l6 and chemotherapy
L7           68 L6 AND CHEMOTHERAPY

=> s l7 and treat?
  20 FILES SEARCHED...
L8           68 L7 AND TREAT?

=> dis l8 1-68 bib abs

L8   ANSWER 1 OF 68  IFIPAT  COPYRIGHT 2004 IFI on STN
AN    10105596  IFIPAT;IFIUDB;IFICDB
TI    COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL
      DISEASES; ADMINISTERING TO A MAMMAL A COMPOSITION CONTAINING
      PYRIMIDINE NUCLEOTIDE PRECURSORS IN AMOUNTS
      SUFFICIENT TO TREAT SYMPTOMS RESULTING FROM MITOCHONDRIAL
      RESPIRATORY CHAIN DEFICIENCIES.
INF   Saydoff; Joel A., Middletown, MD, US
      Von Borstel; Reid W., Potomac, MD, US
IN    Saydoff Joel A; Von Borstel Reid W
PAF   Unassigned
PA    Unassigned Or Assigned To Individual (68000)
AG    NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA,
      22201, US
PI    US 2002049182   A1  20020425
AI    US 2001-930494      20010816
RLI   WO 1999-US19725      19990831 Section 371 PCT Filing UNKNOWN
      US 1998-144096       19980831 CONTINUATION-IN-PART   PENDING
      US 2001-763955       20010228 CONTINUATION-IN-PART   PENDING
```

FI US 2002049182 20020425
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
OS CA 136:319784
CLMN 50
GI 16 Figure(s).
FIG. 1: Survival plot of mice **treated** with 3NP in addition to TAU and/or creatine.
FIG. 2: Survival plot of mice **treated** with 3NP in addition to TAU and/or coenzyme Q10 (CoQ).
FIG. 3: Survival plot of mice **treated** with 3NP in addition to increasing doses of TAU
FIG. 4: The effect of 3NP and TAU and/or creatine on body weight as a percentage of baseline body weight. * Indicates p lessthan 0.05 difference compared to the Vehicle+Vehicle **treatment** group.
FIG. 5: The effect of 3NP and TAU and/or coenzyme Q10 (CoQ) on body weight as a percentage of baseline body weight. There was a p less-than 0.05 difference comparing Vehicle+Vehicle with the Vehicle+3NP groups. There was a p less-than 0.05 difference comparing Vehicle+3NP with the TAU+3NP groups.
FIG. 6: The effect of 3NP and increasing doses of TAU on body weight as a percentage of baseline body weight. There was a p less-than 0.001 difference comparing the Chow+Vehicle to all groups with 3NP.
FIG. 7: The effect of 3NP and TAU and/or creatine on activity. There was a difference for the TAU+3NP and Creatine+3NP groups compared to the Vehicle+Vehicle **treatment** group of p less-than 0.001.
FIG. 8: The effect of 3NP and TAU and/or coenzyme Q10 (CoQ) on activity. There was a decreased activity due to 3NP with p lessthan 0.001 comparing the Vehicle+Vehicle group with all groups **treated** with 3NP.
FIG. 9: The effect of 3NP and increasing doses of TAU on activity. There was a decreased activity due to 3NP with p lessthan 0.001 comparing the Vehicle+Vehicle group with all groups **treated** with 3NP. There was a p=0.05 difference comparing the Vehicle+3NP and the 4% TAU+3NP groups.
FIG. 10: The effect of 3NP with TAU and/or creatine on rotarod performance at 5 RPM. There was a p less-than 0.01 difference compared to the Vehicle+Vehicle **treatment** group compared to the Vehicle+3NP or Creatine+3NP groups.
FIG. 11: The effect of 3NP with TAU and/or creatine on rotarod performance at 10 RPM. There was a p less-than 0.05 difference compared to the Vehicle+Vehicle **treatment** group compared to the Vehicle+3NP group.
FIG. 12: The effect of increasing doses of TAU on rotarod performance at 10 RPM. There was a p less-than 0.001 difference compared to the Vehicle+Vehicle **treatment** group compared to the Vehicle+3NP group. There was a p less-than 0.01 difference of the Vehicle+3NP compared to all of 3NP groups **treated** with TAU.
FIG. 13: Survival plot of mice **treated** with different doses of azide by subcutaneous infusion in addition to TAU. Kaplan-Meier survival plot using the Mantel-Cox test indicates that TAU increased survival at p less-than 0.05 comparing the chow+40 or 80 mu g/hr azide compared to 6% TAU+40 or 80 mu g/hr azide, respectively. TAU also reduced mortality due to 60 mu g/hr azide infusion from 60& to 30% (data not shown).
FIG. 14: The effect of different doses of azide infusion and TAU on body weight as a percentage of baseline body weight. There was a p less-than 0.05 difference comparing Vehicle+Saline with the Vehicle+40 mu g/hr azide groups. There was a p less-than 0. 05 difference comparing Vehicle+40 mu g/hr azide with the TAU+40 mu g/hr azide groups. The high degree of mortality in the Chow+60 and 80 mu g/hr azide groups resulted in a high variability of the body weight in the few surviving animals.
FIG. 15: The effect of TAU on Tunel positive cells in the cerebral cortex of mice infused with 80 mu g/hr azide for 2 weeks. **Treatment** with 6% TAU decreased the dying cells dramatically. Magnification 200 x .
FIG. 16: The effect of increasing concentration of uridine on the survival of NHNP cells cultured in the absence of glucose and an increasing concentration of azide.

AB Compounds, compositions, and methods are provided for **treatment** of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing **pyrimidine**

nucleotide precursors in amounts sufficient to **treat** symptoms resulting from mitochondrial respiratory chain deficiencies.

CLMN 50 16 Figure(s).

FIG. 1: Survival plot of mice **treated** with 3NP in addition to TAU and/or creatine.

FIG. 2: Survival plot of mice **treated** with 3NP in addition to TAU and/or coenzyme Q10 (CoQ).

FIG. 3: Survival plot of mice **treated** with 3NP in addition to increasing doses of TAU

FIG. 4: The effect of 3NP and TAU and/or creatine on body weight as a percentage of baseline body weight. * Indicates p lessthan 0.05 difference compared to the Vehicle+Vehicle **treatment** group.

FIG. 5: The effect of 3NP and TAU and/or coenzyme Q10 (CoQ) on body weight as a percentage of baseline body weight. There was a p less-than 0.05 difference comparing Vehicle+Vehicle with the Vehicle+3NP groups. There was a p less-than 0.05 difference comparing Vehicle+3NP with the TAU+3NP groups.

FIG. 6: The effect of 3NP and increasing doses of TAU on body weight as a percentage of baseline body weight. There was a p less-than 0.001 difference comparing the Chow+Vehicle to all groups with 3NP.

FIG. 7: The effect of 3NP and TAU and/or creatine on activity. There was a difference for the TAU+3NP and Creatine+3NP groups compared to the Vehicle+Vehicle **treatment** group of p less-than 0.001.

FIG. 8: The effect of 3NP and TAU and/or coenzyme Q10 (CoQ) on activity. There was a decreased activity due to 3NP with p lessthan 0.001 comparing the Vehicle+Vehicle group with all groups **treated** with 3NP.

FIG. 9: The effect of 3NP and increasing doses of TAU on activity. There was a decreased activity due to 3NP with p lessthan 0.001 comparing the Vehicle+Vehicle group with all groups **treated** with 3NP. There was a p=0.05 difference comparing the Vehicle+3NP and the 4% TAU+3NP groups.

FIG. 10: The effect of 3NP with TAU and/or creatine on rotarod performance at 5 RPM. There was a p less-than 0.01 difference compared to the Vehicle+Vehicle **treatment** group compared to the Vehicle+3NP or Creatine+3NP groups.

FIG. 11: The effect of 3NP with TAU and/or creatine on rotarod performance at 10 RPM. There was a p less-than 0.05 difference compared to the Vehicle+Vehicle **treatment** group compared to the Vehicle+3NP group.

FIG. 12: The effect of increasing doses of TAU on rotarod performance at 10 RPM. There was a p less-than 0.001 difference compared to the Vehicle+Vehicle **treatment** group compared to the Vehicle+3NP group. There was a p less-than 0.01 difference of the Vehicle+3NP compared to all of 3NP groups **treated** with TAU.

FIG. 13: Survival plot of mice **treated** with different doses of azide by subcutaneous infusion in addition to TAU. Kaplan-Meier survival plot using the Mantel-Cox test indicates that TAU increased survival at p less-than 0.05 comparing the chow+40 or 80 mu g/hr azide compared to 6% TAU+40 or 80 mu g/hr azide, respectively. TAU also reduced mortality due to 60 mu g/hr azide infusion from 60& to 30% (data not shown).

FIG. 14: The effect of different doses of azide infusion and TAU on body weight as a percentage of baseline body weight. There was a p less-than 0.05 difference comparing Vehicle+Saline with the Vehicle+40 mu g/hr azide groups. There was a p less-than 0. 05 difference comparing Vehicle+40 mu g/hr azide with the TAU+40 mu g/hr azide groups. The high degree of mortality in the Chow+60 and 80 mu g/hr azide groups resulted in a high variability of the body weight in the few surviving animals.

FIG. 15: The effect of TAU on Tunel positive cells in the cerebral cortex of mice infused with 80 mu g/hr azide for 2 weeks. **Treatment** with 6% TAU decreased the dying cells dramatically. Magnification 200 x .

FIG. 16: The effect of increasing concentration of uridine on the survival of NHNP cells cultured in the absence of glucose and an increasing concentration of azide.

L8 ANSWER 2 OF 68 IFIPAT COPYRIGHT 2004 IFI on STN

AN 10016574 IFIPAT;IFIUDB;IFICDB

TI COMPOSITIONS AND METHODS FOR **TREATMENT** OF MITOCHONDRIAL DISEASES; ADMINISTERING **PYRIMIDINE NUCLEOTIDE PRECURSOR** WHERE RESPIRATORY CHAIN DYSFUNCTION IS CAUSED BY

MUTATION, DELETION, OR REARRANGEMENT OF MITOCHONDRIAL DNA, CYTOTOXIC CANCER **CHEMOTHERAPY** AGENTS, AGING
INF von Borstel; Reid W., Potomac, MD, US
IN von Borstel Reid W
PAF Pro-Neuron, Inc.
PA Pro-Neuron Inc (31873)
AG Nixon & Vanderhye P.C., 8th Floor, 1100 N. Glebe Rd., Arlington, VA, 22201, US
PI US 2001016576 A1 20010823
AI US 2001-838136 20010420
RLI US 1998-144096 19980831 CONTINUATION
FI US 2001016576 20010823
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 46
AB Compounds, compositions, and methods are provided for **treatment** of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing **pyrimidine nucleotide precursors** in amounts sufficient to **treat** symptoms resulting from mitochondrial respiratory chain deficiencies.
CLMN 46

L8 ANSWER 3 OF 68 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10005714 IFIPAT;IFIUDB;IFICDB
TI COMPOSITIONS AND METHODS FOR **TREATMENT** OF MITOCHONDRIAL DISEASES; PREVENTING OR **TREATING** PATHOPHYSIOLOGICAL CONSEQUENCES OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION IN A MAMMAL BY ADMINISTERING A **PYRIMIDINE NUCLEOTIDE PRECURSOR; TREATING CHEMOTHERAPY SIDE EFFECTS**, FOR EXAMPLE
INF VON BORSTEL; REID W., POTOMAC, MD, US
IN VON BORSTEL REID W
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
PPA Pro-Neuron Inc (Probable)
AG NIXON & VANDERHYE, 1100 N. GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA, 22201
PI US 2001005719 A1 20010628
AI US 1998-144096 19980831
FI US 2001005719 20010628
US 6472378 20021029
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 46
AB Compounds, compositions, and methods are provided for **treatment** of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing **pyrimidine nucleotide precursors** in amounts sufficient to **treat** symptoms resulting from mitochondrial respiratory chain deficiencies.
CLMN 46

L8 ANSWER 4 OF 68 IFIPAT COPYRIGHT 2004 IFI on STN
AN 03775856 IFIPAT;IFIUDB;IFICDB
TI COMPOSITIONS AND METHODS FOR **TREATMENT** OF MITOCHONDRIAL DISEASES; PREVENTING OR **TREATING** PATHOPHYSIOLOGICAL CONSEQUENCES OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION IN A MAMMAL BY ADMINISTERING A **PYRIMIDINE NUCLEOTIDE PRECURSOR; TREATING CHEMOTHERAPY SIDE EFFECTS**, FOR EXAMPLE
INF von Borstel; Reid W., Potomac, MD
IN von Borstel Reid W
PAF Pro-Neuron, Inc., Gaithersburg, MD
PA Pro-Neuron Inc (31873)
EXNAM Ketter, James
EXNAM Schnizer, Richard
AG Nixon & Vanderhye
PI US 6472378 B2 20021029

US 2001005719 A1 20010628
AI US 1998-144096 19980831
XPD 31 Aug 2018
FI US 6472378 20021029
US 2001005719 20010628
DT Utility; CERTIFICATE OF CORRECTION
CDAT 8 Apr 2003
FS CHEMICAL
GRANTED
MRN 009653 MFN: 0832
NTE INDEXED FROM APPLICATION
CLMN 8
AB Compounds, compositions, and methods are provided for **treatment** of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing **pyrimidine nucleotide precursors** in amounts sufficient to **treat** symptoms resulting from mitochondrial respiratory chain deficiencies.
NTE INDEXED FROM APPLICATION
CLMN 8

L8 ANSWER 5 OF 68 PASCAL COPYRIGHT 2004 INIST-CNRS. ALL RIGHTS RESERVED. on STN
AN 1999-0158285 PASCAL
CP Copyright .COPYRGT. 1999 INIST-CNRS. All rights reserved.
TIEN Short-term **treatment** with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects : a preliminary report
AU RENSHAW P. F.; DANIELS S.; LUNDAHL L. H.; ROGERS V.; LUKAS S. E.
CS Brain Imaging Center, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, United States; Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School, East House 111, 115 Mill Street, Belmont, MA 02478, United States
SO Psychopharmacologia, (1999), 142(2), 132-138, 40 refs.
ISSN: 0033-3158
DT Journal
BL Analytic
CY Germany, Federal Republic of
LA English
AV INIST-1761, 354000073871950030
CP Copyright .COPYRGT. 1999 INIST-CNRS. All rights reserved.
AB The administration of cytidine-5'-diphosphate choline (CDP-choline, citicoline) to animals increases the rate of membrane phospholipid synthesis and elevates brain dopamine levels. Because cocaine dependence has been associated with increases in brain phospholipid **precursors**, as well as depletion of dopamine within the central nervous system, the present outpatient study was conducted to assess the safety of citicoline (500 mg bid) and to determine if short-term **treatment** alters mood states and cocaine craving in subjects with a history of cocaine dependence. In addition, measures of drug craving and mood states after presentation of cocaine-related cues were collected on two occasions: before and after 14 days of double-blind **treatment** with either citicoline or placebo. Subjects did not experience any **side effects** and citicoline **treatment** was associated with decreases in self-reported mood states associated with cocaine craving. These preliminary data are encouraging and suggest that citicoline warrants further study as a promising potential **treatment** for cocaine abuse and dependence that is devoid of **side effects**.

L8 ANSWER 6 OF 68 USPATFULL on STN
AN 2004:114177 USPATFULL
TI Compositions and methods for cell dedifferentiation and tissue regeneration
IN Keating, Mark T., Chestnut Hill, MA, UNITED STATES
Odelberg, Shannon J., Salt Lake City, UT, UNITED STATES
Poss, Kenneth D., Brookline, MA, UNITED STATES
PA University of Utah Research Foundation, Salt Lake City, UT, UNITED STATES, 84112 (U.S. corporation)
PI US 2004087016 A1 20040506

AI US 2002-302812 A1 20021122 (10)
RLI Continuation-in-part of Ser. No. US 2003-275828, filed on 4 Apr 2003, PENDING A 371 of International Ser. No. WO 2001-US15582, filed on 14 May 2001, PENDING
PRAI US 2000-204080P 20000512 (60)
US 2000-204081P 20000512 (60)
US 2000-204082P 20000512 (60)
DT Utility
FS APPLICATION
LREP ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
CLMN Number of Claims: 63
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10731
AB The present invention provides methods and compositions to dedifferentiate a cell. The ability of the methods and compositions of the present invention to promote the dedifferentiation of differentiated cells, including terminally differentiated cells, can be used to promote regeneration of tissues and organs in vivo. The ability of the methods and compositions of the present invention to promote the dedifferentiation of differentiated cells, including terminally differentiated cells, can further be used to produce populations of stem or progenitor cells which can be used to promote regeneration of tissues and/or organs damaged by injury or disease. Accordingly, the present invention provides novel methods for the **treatment** of a wide range of injuries and diseases that affect many diverse cell types.

L8 ANSWER 7 OF 68 USPATFULL on STN
AN 2004:107661 USPATFULL
TI Drug metabolizing enzymes
IN Astromoff, Anna, San Carlos, CA, UNITED STATES
Au-Young, Janice K, Brisbane, CA, UNITED STATES
Baughn, Mariah R, Los Angeles, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Duggan, Brendan M, Sunnyvale, CA, UNITED STATES
Forsythe, Ian J, Edmonton, CANADA
Gietzen, Kimberly J, San Jose, CA, UNITED STATES
Griffin, Jennifer A, Fremont, CA, UNITED STATES
Lee, Ernestine A, Castro Valley, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Richardson, Thomas W, Redwood City, CA, UNITED STATES
Ring, Huijun Z, Foster City, CA, UNITED STATES
Sanjanwala, Madhusudan M, Los Altos, CA, UNITED STATES
Swarnakar, Anita, San Francisco, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Warren, Bridget A, San Marcos, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Zebarjadian, Yeganeh, San Francisco, CA, UNITED STATES
PI US 2004082061 A1 20040429
AI US 2003-468125 A1 20030815 (10)
WO 2002-US4918 20020214
DT Utility
FS APPLICATION
LREP INCYTE CORPORATION, 3160 PORTER DRIVE, PALO ALTO, CA, 94304
CLMN Number of Claims: 79
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8016
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides human drug metabolizing enzymes (DME) and polynucleotides which identify and encode DME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, **treating**, or preventing disorders associated with aberrant expression of DME.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 68 USPATFULL on STN
AN 2004:101228 USPATFULL
TI Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
IN Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
PI US 2004077090 A1 20040422
AI US 2003-383798 A1 20030306 (10)
RLI Continuation of Ser. No. US 2000-677584, filed on 30 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-594459, filed on 14 Jun 2000, GRANTED, Pat. No. US 6605449 Continuation-in-part of Ser. No. US 2000-522289, filed on 9 Mar 2000, GRANTED, Pat. No. US 6358709 Continuation-in-part of Ser. No. US 2000-498557, filed on 4 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2000-495052, filed on 31 Jan 2000, GRANTED, Pat. No. US 6479258
PRAI US 1999-156815P 19990929 (60)
DT Utility
FS APPLICATION
LREP HALE AND DORR LLP, 300 PARK AVENUE, NEW YORK, NY, 10022
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 37121
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. Also, a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, thus conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. Furthermore, a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 68 USPATFULL on STN
AN 2004:64489 USPATFULL
TI Templated molecules and methods for using such molecules
IN Pedersen, Henrik, Bagsvaerd, DENMARK
Gouilaev, Alex Haahr, Vesko Sjaelland, DENMARK
Franch, Thomas, Odense C, DENMARK
Sams, Christian Klarner, Frederiksberg C, DENMARK
Olsen, Eva Kampmann, Herlev, DENMARK
Slok, Frank Abilgaard, Kobenhavn N, DENMARK
Husemoen, Gitte Nystrup, Kobenhavn N, DENMARK
Felding, Jakob, Charlottenlund, DENMARK
Hyldtoft, Lene, Virum, DENMARK
Norregaard-Madsen, Mads, Birkerod, DENMARK
Godskesen, Michael Anders, Vedbaek, DENMARK
Glad, Sanne Schroder, Ballerup, DENMARK
Thisted, Thomas, Frederikssund, DENMARK
Freskgard, Per-Ola, Vellinge, SWEDEN
Holtmann, Anette, Ballerup, DENMARK
PA Nuevolution A/S, Copenhagen, DENMARK (non-U.S. corporation)
PI US 2004049008 A1 20040311
AI US 2002-175539 A1 20020620 (10)
PRAI DK 2001-962 20010620
US 2001-299443P 20010621 (60)
US 2002-364056P 20020315 (60)
DT Utility
FS APPLICATION
LREP BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303
CLMN Number of Claims: 316
ECL Exemplary Claim: 1
DRWN 100 Drawing Page(s)

LN.CNT 11215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for synthesising templated molecules. In one aspect of the invention, the templated molecules are linked to the template which templated the synthesis thereof. The intion allows the generation of libraries which can be screened for e.g. therapeutic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 68 USPATFULL on STN
AN 2004:44988 USPATFULL
TI **Pyrimidine nucleotide precursors** for **treatment** of systemic inflammation and inflammatory hepatitis
IN von Borstel, Reid W., Potomac, MD, UNITED STATES
Bamat, Michael K., Potomac, MD, UNITED STATES
Hiltbrand, Bradley M., Columbia, MD, UNITED STATES
PA Pro-Neuron Inc. (U.S. corporation)
PI US 2004033981 A1 20040219
AI US 2003-601863 A1 20030624 (10)
RLI Continuation of Ser. No. US 1994-266897, filed on 1 Jul 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-158799, filed on 1 Dec 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-987730, filed on 8 Dec 1992, ABANDONED Continuation-in-part of Ser. No. US 1990-438493, filed on 26 Jun 1990, ABANDONED Continuation-in-part of Ser. No. US 1987-115929, filed on 28 Oct 1987, ABANDONED
DT Utility
FS APPLICATION
LREP NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA, 22201-4714
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1972
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Pyrimidine nucleotide precursors** including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 68 USPATFULL on STN
AN 2004:12638 USPATFULL
TI Antisense therapy using oligonucleotides that target human kinesin genes for **treatment** of cancer
IN Reinhard, Christoph, Alameda, CA, UNITED STATES
Walter, Annette, San Carlos, CA, UNITED STATES
PI US 2004009156 A1 20040115
AI US 2002-269021 A1 20021010 (10)
PRAI US 2001-328444P 20011012 (60)
DT Utility
FS APPLICATION
LREP Steven W. Collier, Chiron Corporation, 4560 Horton Street, Emeryville, CA, 94608-2916
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2052
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed toward the use of antisense oligonucleotides that target human kinesin genes for **treating** diseases involving aberrant cell proliferation, particularly cancers such as colon cancer. Also, the invention is directed to a synergistic combination for **treating** cancer comprising a chemotherapeutic such as cisplatin and an antisense oligonucleotide that specifically inhibits human kinesin expression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 68 USPATFULL on STN
AN 2003:330562 USPATFULL
TI Phosphatidylinositol-4-phosphate 5-kinase, type II beta inhibitors for inhibiting angiogenesis
IN Marcusson, Eric G., San Diego, CA, UNITED STATES
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Freier, Susan M., San Diego, CA, UNITED STATES
PI US 2003232777 A1 20031218
AI US 2003-348073 A1 20030116 (10)
RLI Continuation-in-part of Ser. No. US 2002-175627, filed on 18 Jun 2002, PENDING
DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE - 46TH FLOOR, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4778
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions and methods are provided for modulating the expression of phosphatidylinositol-4-phosphate 5-kinase, type II beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, type II beta. Methods of using these compounds for modulation of phosphatidylinositol-4-phosphate 5-kinase, type II beta expression and for diagnosis and **treatment** of disease associated with expression of phosphatidylinositol-4-phosphate 5-kinase, type II beta are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 68 USPATFULL on STN
AN 2003:326931 USPATFULL
TI Thymidylate synthase gene sequence variances having utility in determining the **treatment** of disease
IN Stanton, Jr., Vincent P., Belmont, MA, United States
PA Nuvelo, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6664062 B1 20031216
AI US 2001-963333 20010924 (9)
RLI Division of Ser. No. US 2000-658659, filed on 8 Sep 2000 Continuation-in-part of Ser. No. US 2000-596033, filed on 15 Jun 2000, now abandoned Continuation-in-part of Ser. No. US 1999-357743, filed on 20 Jul 1999, now abandoned Continuation-in-part of Ser. No. US 1999-357024, filed on 19 Jul 1999, now abandoned
PRAI US 1998-93484P 19980720 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Myers, Carla J.; Assistant Examiner: Chakrabarti, Arun Kr.
LREP Fish & Richardson PC
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 8370
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure describes the use of genetic variance information for folate transport or metabolism genes or pyrimidine transport or metabolism genes in the selection of effective methods of **treatment** of a disease or condition. The variance information is indicative of the expected response of a patient to a method of **treatment**. Methods of determining relevant variance information and additional methods of using such variance information are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 68 USPATFULL on STN
AN 2003:319270 USPATFULL
TI Notch1 inhibitors for inducing apoptosis
IN Freier, Susan M., San Diego, CA, UNITED STATES

Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Koller, Erich, Carlsbad, CA, UNITED STATES
PI US 2003225019 A1 20031204
AI US 2003-348750 A1 20030121 (10)
RLI Continuation-in-part of Ser. No. US 2002-160497, filed on 30 May 2002, PENDING
DT Utility
FS APPLICATION
LREP Licata & Tyrrell P.C., 66 E. Main Street, Marlton, NJ, 08053
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5687
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions and methods are provided for modulating the expression of Notch1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Notch1. Methods of using these compounds for modulation of Notch1 expression and for diagnosis and **treatment** of disease associated with expression Notch1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 68 USPATFULL on STN
AN 2003:311849 USPATFULL
TI Nucleic acid and corresponding protein entited 125P5C8 useful in **treatment** and detection of cancer
IN Faris, Mary, Los Angeles, CA, UNITED STATES
Challita-Eid, Pia M., Encino, CA, UNITED STATES
Hubert, Rene S., Los Angeles, CA, UNITED STATES
Afar, Daniel E. H., Brisbane, CA, UNITED STATES
Raitano, Arthur B., Los Angeles, CA, UNITED STATES
Ge, Wangmao, Culver City, CA, UNITED STATES
Morrison, Robert Kendall, Santa Monica, CA, UNITED STATES
Morrison, Karen Jane Meyrick, Santa Monica, CA, UNITED STATES
Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
PI US 2003219444 A1 20031127
AI US 2002-99460 A1 20020313 (10)
RLI Continuation-in-part of Ser. No. US 2001-809638, filed on 14 Mar 2001, PENDING
DT Utility
FS APPLICATION
LREP Kate H. Murashige, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 46 Drawing Page(s)
LN.CNT 11234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 68 USPATFULL on STN
AN 2003:306901 USPATFULL
TI Composition and imaging methods for pharmacokinetic and pharmacodynamic evaluation of therapeutic delivery system
IN Hallahan, Dennis E., Nashville, TN, UNITED STATES
PA Vanderbilt University (U.S. corporation)
PI US 2003216337 A1 20031120
AI US 2003-342805 A1 20030115 (10)
PRAI US 2002-348945P 20020115 (60)

DT Utility
FS APPLICATION
LREP JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2902
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A halogen-labeled gene therapy construct that includes halogen-labeled nucleic acids, methods for preparing a halogenated gene therapy construct, and methods for in vivo imaging of the same. Also provided are methods for non-invasive drug detection in a subject using a labeled antibody that recognizes a heterologous antigen conjugated to, encoded by, or otherwise associated with the drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 68 USPATFULL on STN
AN 2003:300810 USPATFULL
TI **Pyrimidine nucleotide precursors** for **treatment** of systemic inflammation and inflammatory heptitis
IN von Borstel, Reid W., Potomac, MD, UNITED STATES
Bamat, Michael K., Potomac, MD, UNITED STATES
Hiltbrand, Bradley M., Columbia, MD, UNITED STATES
PA Pro Neuron, Inc. (U.S. corporation)
PI US 2003212036 A1 20031113
AI US 2003-421831 A1 20030424 (10)
RLI Division of Ser. No. US 2000-702876, filed on 1 Nov 2000, PENDING Continuation of Ser. No. US 1995-479519, filed on 7 Jun 1995, GRANTED, Pat. No. US 6232298 Division of Ser. No. US 1994-266897, filed on 1 Jul 1994, ABANDONED
DT Utility
FS APPLICATION
LREP NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA, 22201-4714
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1966
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Pyrimidine nucleotide precursors** including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 68 USPATFULL on STN
AN 2003:300802 USPATFULL
TI Immunomodulatory polynucleotides in **treatment** of an infection by an intracellular pathogen
IN Raz, Eyal, Del Mar, CA, UNITED STATES
Kornbluth, Richard, La Jolla, CA, UNITED STATES
Catanzaro, Antonino, San Diego, CA, UNITED STATES
Hayashi, Tomoko, San Diego, CA, UNITED STATES
Carson, Dennis, Del Mar, CA, UNITED STATES
PI US 2003212028 A1 20031113
AI US 2003-353917 A1 20030128 (10)
RLI Continuation of Ser. No. US 2001-774403, filed on 30 Jan 2001, GRANTED, Pat. No. US 6552006
PRAI US 2000-179353P 20000131 (60)
DT Utility
FS APPLICATION
LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2075
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention features methods for **treatment** or prevention of infection by intracellular pathogens (e.g., Mycobacterium species) by administration of an immunomodulatory nucleic acid molecule. In one embodiment, immunomodulatory nucleic acid molecule are administered in combination with another anti-pathogenic agent to provide a synergistic anti-pathogenic effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 68 USPATFULL on STN
AN 2003:251600 USPATFULL
TI Method for **treating** inflammatory bowel disease and other forms of gastrointestinal inflammation
IN Raz, Eyal, Del Mar, CA, UNITED STATES
Rachmilewitz, Daniel, Tel Aviv, ISRAEL
PI US 2003176389 A1 20030918
AI US 2003-412151 A1 20030411 (10)
RLI Continuation of Ser. No. US 2001-791500, filed on 22 Feb 2001, PENDING
PRAI US 2000-184256P 20000223 (60)
DT Utility
FS APPLICATION
LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1769
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method for ameliorating gastrointestinal inflammation, particularly chronic gastrointestinal inflammation such as inflammatory bowel disease (IBD), in a subject. In one embodiment, the method comprises administering an immunomodulatory nucleic acid to a subject suffering from or susceptible to gastrointestinal inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 68 USPATFULL on STN
AN 2003:251164 USPATFULL
TI RNA interference mediated inhibition of HIV gene expression using short interfering RNA
IN McSwiggen, James A., Boulder, CO, UNITED STATES
PI US 2003175950 A1 20030918
AI US 2002-225023 A1 20020821 (10)
RLI Continuation-in-part of Ser. No. US 2002-157580, filed on 29 May 2002, PENDING
PRAI US 2002-398036P 20020723 (60)
US 2001-294140P 20010529 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 5114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns methods and reagents useful in modulating HIV gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against HIV polypeptide and polynucleotide targets.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 68 USPATFULL on STN
AN 2003:240449 USPATFULL
TI Oligoribonucleotides with enzymatic activity
IN Beigelman, Leonid, Broomfield, CO, United States
Burgin, Alex B., Chula Vista, CA, United States

Beaudry, Amber, Broomfield, CO, United States
Karpeisky, Alexander, Lafayette, CO, United States
Matulic-Adamic, Jasenka, Boulder, CO, United States
Sweedler, David, Louisville, CO, United States
Zinnen, Shawn, Denver, CO, United States
PA Sirna Therapeutics, Inc., Boulder, CO, United States (U.S. corporation)
PI US 6617438 B1 20030909
AI US 1999-476387 19991230 (9)
RLI Continuation-in-part of Ser. No. US 1999-474432, filed on 29 Dec 1999, now patented, Pat. No. US 6528640 Continuation-in-part of Ser. No. US 1999-301511, filed on 28 Apr 1999, now patented, Pat. No. US 6482932 Continuation-in-part of Ser. No. US 1998-186675, filed on 4 Nov 1998, now patented, Pat. No. US 6127535
PRAI US 1998-83727P 19980429 (60)
US 1997-64866P 19971105 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Crane, L E
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 22 Drawing Figure(s); 21 Drawing Page(s)
LN.CNT 4484
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel nucleotide triphosphates, methods of synthesis and process of incorporating these nucleotide triphosphates into oligonucleotides, and isolation of novel nucleic acid catalysts (e.g., ribozymes) are disclosed. Also, described are the use of novel enzymatic nucleic acid molecules to inhibit HER2/neu/ErbB2 gene expression and their applications in human therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 68 USPATFULL on STN
AN 2003:188424 USPATFULL
TI Method for **treating** inflammatory bowel disease and other forms of gastrointestinal inflammation
IN Raz, Eyal, Del Mar, CA, UNITED STATES
Rachmilewitz, Daniel, Tel Aviv, ISRAEL
PI US 2003130217 A1 20030710
AI US 2002-219143 A1 20020813 (10)
RLI Continuation-in-part of Ser. No. US 2001-791500, filed on 22 Feb 2001, PENDING
PRAI US 2000-184256P 20000223 (60)
DT Utility
FS APPLICATION
LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method for ameliorating gastrointestinal inflammation, particularly chronic gastrointestinal inflammation such as inflammatory bowel disease (IBD), in a subject. In one embodiment, the method comprises administering an immunomodulatory nucleic acid to a subject suffering from or susceptible to gastrointestinal inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 68 USPATFULL on STN
AN 2003:188393 USPATFULL
TI Conjugates and compositions for cellular delivery
IN Vargeese, Chandra, Thornton, CO, UNITED STATES
Matulic-Adamic, Jasenka, Boulder, CO, UNITED STATES
Karpeisky, Alexander, Lafayette, CO, UNITED STATES
Beigelman, Leonid, Longmont, CO, UNITED STATES
Blatt, Lawrence, Boulder, CO, UNITED STATES
Zinnen, Shawn, Denver, CO, UNITED STATES

PI US 2003130186 A1 20030710
AI US 2002-201394 A1 20020722 (10)
PRAI US 2001-311865P 20010813 (60)
US 2001-306883P 20010720 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 4466
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin (HSA) derived conjugates of biologically active compounds, including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 68 USPATFULL on STN
AN 2003:166546 USPATFULL
TI Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
IN Janjic, Nebojsa, Boulder, CO, UNITED STATES
Gold, Larry, Bouler, CO, UNITED STATES
Schmidt, Paul, Niwot, CO, UNITED STATES
Vargeese, Chandra, Thornton, CO, UNITED STATES
Willis, Michael, Louisville, CO, UNITED STATES
PA Gilead Sciences, Inc. (U.S. corporation)
PI US 2003114404 A1 20030619
AI US 2002-205009 A1 20020725 (10)
RLI Division of Ser. No. US 2000-254968, filed on 13 Mar 2000, GRANTED, Pat. No. US 6426335 A 371 of International Ser. No. WO 1997-US18944, filed on 17 Oct 1997, PENDING Continuation-in-part of Ser. No. US 1996-739109, filed on 25 Oct 1996, GRANTED, Pat. No. US 5859228 Continuation-in-part of Ser. No. US 1997-870930, filed on 6 Jun 1997, GRANTED, Pat. No. US 6168778 Continuation-in-part of Ser. No. US 1997-897341, filed on 21 Jul 1997, GRANTED, Pat. No. US 6092764
DT Utility
FS APPLICATION
LREP SWANSON & BRATSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129
CLMN Number of Claims: 84
ECL Exemplary Claim: 1
DRWN 34 Drawing Page(s)
LN.CNT 4494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 68 USPATFULL on STN
AN 2003:160082 USPATFULL
TI Novel phosphoramidate compounds and methods of use
IN Shepard, H. Michael, Encinitas, CA, UNITED STATES
Vaino, Andrew Rein, San Diego, CA, UNITED STATES

Lehsten, Danielle M., San Diego, CA, UNITED STATES
PI US 2003109697 A1 20030612
AI US 2002-119927 A1 20020409 (10)
RLI Continuation-in-part of Ser. No. US 2001-782721, filed on 12 Feb 2001, PENDING Continuation of Ser. No. US 1999-235961, filed on 22 Jan 1999, GRANTED, Pat. No. US 6339151
PRAI US 1998-72264P 19980123 (60)
US 1998-76950P 19980305 (60)
US 1998-108634P 19981116 (60)
DT Utility
FS APPLICATION
LREP McCutchen, Doyle, Brown & Enersen LLP, Suite 1800, Three Embarcadero Center, San Francisco, CA, 94111
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 3503
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides compounds, compositions and methods for **treating** cancer, infectious disease, an autoimmune disorder or an inflammatory condition. Therapeutic compounds useful in the methods of this invention are 5'-phosphoramidatyl, 1,5-substituted pyrimidine compounds, derivatives, analogs and pharmaceutically acceptable salts thereof

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 68 USPATFULL on STN
AN 2003:153640 USPATFULL
TI Nucleoside triphosphates and their incorporation into oligonucleotides
IN Beigelman, Leonid, Longmont, CO, UNITED STATES
Zinnen, Shawn, Denver, CO, UNITED STATES
PI US 2003105308 A1 20030605
AI US 2001-918728 A1 20010731 (9)
RLI Continuation-in-part of Ser. No. US 2001-825805, filed on 4 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-578223, filed on 23 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-476387, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-474432, filed on 29 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-301511, filed on 28 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-186675, filed on 4 Nov 1998, GRANTED, Pat. No. US 6127535
PRAI US 1998-83727P 19980429 (60)
US 1997-64866P 19971105 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 2564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel nucleotide triphosphates, methods of synthesis and process of incorporating these nucleotide triphosphates into oligonucleotides, and isolation of novel nucleic acid catalysts (e.g., ribozymes or DNAzymes). Also, provided are the use of novel enzymatic nucleic acid molecules to inhibit gene expression and their applications in human therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 68 USPATFULL on STN
AN 2003:133489 USPATFULL
TI Combination **treatment** of pancreatic cancer
IN Gevas, Philip C., Key Biscayne, FL, UNITED STATES
Michaeli, Dov, Larkspur, CA, UNITED STATES
Grimes, Stephen, Davis, CA, UNITED STATES
Caplin, Martyn, London, UNITED KINGDOM
PI US 2003091574 A1 20030515
AI US 2002-104607 A1 20020322 (10)

PRAI US 2001-278294P 20010323 (60)
DT Utility
FS APPLICATION
LREP WHITE & CASE LLP, PATENT DEPARTMENT, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1633
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A combination for use in the **treatment** of pancreatic cancer comprising:

(i) an anti-gastrin effective immunogenic composition; and,

(ii) one or more chemotherapeutic agents suitable for inhibiting cancer growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 68 USPATFULL on STN
AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
US 2001-305484P 20010712 (60)
US 2001-265305P 20010130 (60)
US 2001-267568P 20010209 (60)
US 2001-313999P 20010820 (60)
US 2001-291631P 20010516 (60)
US 2001-287112P 20010428 (60)
US 2001-278651P 20010321 (60)
US 2001-265682P 20010131 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or **treatment** of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 68 USPATFULL on STN
AN 2003:81585 USPATFULL
TI Folylpolyglutamate synthetase gene sequence variances having utility in determining the **treatment** of disease
IN Stanton, Jr., Vincent P., Belmont, MA, United States
PA Variagenics, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6537759 B1 20030325
AI US 2001-962665 20010924 (9)

RLI Division of Ser. No. US 2000-658659, filed on 8 Sep 2000
Continuation-in-part of Ser. No. US 2000-596033, filed on 15 Jun 2000
Continuation-in-part of Ser. No. US 1999-357743, filed on 20 Jul 1999, now abandoned Continuation-in-part of Ser. No. US 1999-357024, filed on 19 Jul 1999, now abandoned
PRAI US 1998-93484P 19980720 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Chakrabarti, Arun K.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 8362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure describes the use of genetic variance information for folate transport or metabolism genes or pyrimidine transport or metabolism genes in the selection of effective methods of **treatment** of a disease or condition. The variance imformation is indicative of the expected response of a patient to a method of **treatment**. Methods of determining relevant variance information and additional methods of using such variance information are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 30 OF 68 USPATFULL on STN
AN 2003:60295 USPATFULL
TI Synthetic ribonucleic acids with RNAse activity
IN Beigelman, Leonid, Broomfield, CO, United States
Burgin, Alex, Chula Vista, CA, United States
Beaudry, Amber, Broomfield, CO, United States
Karpeisky, Alexander, Lafayette, CO, United States
Matulic-Adamic, Jasenka, Boulder, CO, United States
Sweedler, David, Louisville, CO, United States
Zinnen, Shawn, Denver, CO, United States
PA Ribozyme Pharmaceuticals, incorporated, Boulder, CO, United States (U.S. corporation)
PI US 6528640 B1 20030304
AI US 1999-474432 19991229 (9)
RLI Continuation-in-part of Ser. No. US 1999-301511, filed on 28 Apr 1999
Continuation-in-part of Ser. No. US 1998-186675, filed on 4 Nov 1998, now patented, Pat. No. US 6127535
PRAI US 1998-83727P 19980429 (60)
US 1997-64866P 19971105 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Crane, L. E.
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 3
ECL Exemplary Claim: 1,2
DRWN 23 Drawing Figure(s); 21 Drawing Page(s)
LN.CNT 3964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel nucleotide triphosphates, methods of synthesis and process of incorporating these nucleotide triphosphates into oligonucleotides, and isolation of novel nucleic acid catalysts (e.g., ribozymes) are disclosed. Also, described are the use of novel enzymatic nucleic acid molecules to inhibit HER2/neu/ErbB2 gene expression and their applications in human therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 68 USPATFULL on STN
AN 2003:4083 USPATFULL
TI Nucleotide triphosphates and their incorporation into oligonucleotides
IN Beigelman, Leonid, Longmont, CO, UNITED STATES
Burgin, Alex, San Diego, CA, UNITED STATES
Beaudry, Amber, Denver, CO, UNITED STATES

Karpeisky, Alexander, Lafayette, CO, UNITED STATES
Matulic-Adamic, Jasenka, Boulder, CO, UNITED STATES
Sweedler, David, Louisville, CO, UNITED STATES
Zinnen, Shawn, Denver, CO, UNITED STATES
PI US 2003004122 A1 20030102
AI US 2001-825805 A1 20010404 (9)
RLI Continuation-in-part of Ser. No. US 2000-578223, filed on 23 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-476387, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-474432, filed on 29 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-301511, filed on 28 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-186675, filed on 4 Nov 1998, GRANTED, Pat. No. US 6127535
PRAI US 1998-83727P 19980429 (60)
US 1997-64866P 19971105 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 33 Drawing Page(s)
LN.CNT 5252
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel nucleotide triphosphates, methods of synthesis and process of incorporating these nucleotide triphosphates into oligonucleotides, and isolation of novel nucleic acid catalysts (e.g., ribozymes or DNAzymes). Also, provided are the use of novel enzymatic nucleic acid molecules to inhibit HER2/neu/ErbB2 gene expression and their applications in human therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 68 USPATFULL on STN
AN 2002:295128 USPATFULL
TI Methods and compositions for antisense VEGF oligonucleotides
IN Gill, Parkash S., Agoura, CA, UNITED STATES
Masood, Rizwan, San Gabriel, CA, UNITED STATES
PI US 2002165174 A1 20021107
AI US 2001-805761 A1 20010313 (9)
RLI Continuation of Ser. No. WO 2001-US19, filed on 19 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. US 2000-487023, filed on 19 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1998-16541, filed on 30 Jan 1998, UNKNOWN
PRAI US 1997-37004P 19970131 (60)
DT Utility
FS APPLICATION
LREP McCutchen, Doyle, Brown & Enersen, LLP, Suite1800, Three Embarcadero Center, San Francisco, CA, 94111
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 2620
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to compositions and methods for inhibition of abnormal proliferation of cells or angiogenesis. More particularly this invention provides VEGF antisense oligonucleotides capable of inhibiting proliferation of cancer cells or angiogenesis or combinations thereof. also provided are screening and prognostic assays, as well kits comprising the VEGF antisense oligonucleotides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 33 OF 68 USPATFULL on STN
AN 2002:235524 USPATFULL
TI Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
IN Housman, David E., Newton, MA, UNITED STATES
Ledley, Fred D., Needham, MA, UNITED STATES
Stanton, Vincent P., JR., Belmont, MA, UNITED STATES
PA Variagenics, Inc., a Delaware corporation (U.S. corporation)

PI US 2002127714 A1 20020912
AI US 2001-782837 A1 20010214 (9)
RLI Division of Ser. No. US 1998-45054, filed on 19 Mar 1998, PATENTED
DT Utility
FS APPLICATION
LREP ANITA L. MEIKLEJOHN, PH.D., FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 3790
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for the **treatment** of proliferative disorders using compounds and/or environmental conditions which result in a difference in sensitivity of targeted and non-targeted cells. Certain of the methods involve the identification and use of allele-specific inhibitors of conditionally essential genes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 34 OF 68 USPATFULL on STN
AN 2002:188340 USPATFULL
TI Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
IN Janjic, Nebojsa, Boulder, CO, United States
Gold, Larry, Boulder, CO, United States
Schmidt, Paul, Niwot, CO, United States
Vargeese, Chandra, Thornton, CO, United States
Willis, Michael, Louisville, CO, United States
PA Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)
PI US 6426335 B1 20020730
WO 9818480 19980507
AI US 2000-254968 20000313 (9)
WO 1997-US18944 19971017
20000313 PCT 371 date
DT Utility
FS GRANTED
EXNAM Primary Examiner: Zitomer, Stephanie
LREP Swanson & Bratschun, LLC
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 39 Drawing Figure(s); 34 Drawing Page(s)
LN.CNT 4107
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 35 OF 68 USPATFULL on STN
AN 2002:168075 USPATFULL
TI Mutants of thymidylate synthase and uses thereof
IN Liu-Chen, Xinyue, New York, NY, United States
Tong, Youzhi, Union, NJ, United States
Bertino, Joseph R., Branford, CT, United States
Banerjee, Debabrata, Bellerose, NY, United States
PA Sloan Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 6416987 B1 20020709
WO 9833518 19980806
AI US 1999-367007 19990804 (9)
WO 1998-US2145 19980203
19991015 PCT 371 date

PRAI US 1997-37163P 19970204 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Walicka, Malgorzata A
LREP Adler, Benjamin Aaron
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a mutated human TS, said mutated synthase differing from wild type TS at amino acid residue 49, amino acid residue 52, amino acid residue 108, amino acid residue 221 or amino acid residue 225. Also provided is cDNA mutated human TSs and novel vectors and host cells and methods of using the mutated human TSs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 36 OF 68 USPATFULL on STN
AN 2002:164677 USPATFULL
TI Immunomodulatory polynucleotides in **treatment** of an infection by an intracellular pathogen
IN Raz, Eyal, Del Mar, CA, UNITED STATES
Kornbluth, Richard, La Jolla, CA, UNITED STATES
Catanzaro, Antonino, San Diego, CA, UNITED STATES
Hayashi, Tomoko, San Diego, CA, UNITED STATES
Carson, Dennis, Del Mar, CA, UNITED STATES
PI US 2002086295 A1 20020704
US 6552006 B2 20030422
AI US 2001-774403 A1 20010130 (9)
PRAI US 2000-179353P 20000131 (60)
DT Utility
FS APPLICATION
LREP Carol L. Francis, BOZICEVIC, FIELD & FRANCIS LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA, 94025
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features methods for **treatment** or prevention of infection by intracellular pathogens (e.g., Mycobacterium species) by administration of an immunomodulatory nucleic acid molecule. In one embodiment, immunomodulatory nucleic acid molecule are administered in combination with another anti-pathogenic agent to provide a synergistic anti-pathogenic effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 37 OF 68 USPATFULL on STN
AN 2002:105955 USPATFULL
TI 57658, a novel human uridine kinase and uses thereof
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
PI US 2002055161 A1 20020509
AI US 2001-896522 A1 20010628 (9)
PRAI US 2000-216503P 20000630 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 3955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 57658 nucleic acid molecules, which encode novel uridine kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57658 nucleic acid molecules,

host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 57658 gene has been introduced or disrupted. The invention still further provides isolated 57658 proteins, fusion proteins, antigenic peptides and anti-57658 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 38 OF 68 USPATFULL on STN
AN 2002:92658 USPATFULL
TI Compositions and methods for **treatment** of mitochondrial diseases
IN Von Borstel, Reid W., Potomac, MD, UNITED STATES
Saydoff, Joel A., Middletown, MD, UNITED STATES
PI US 2002049182 A1 20020425
AI US 2001-930494 A1 20010816 (9)
RLI Continuation-in-part of Ser. No. US 2001-763955, filed on 28 Feb 2001, PENDING A 371 of International Ser. No. WO 1999-US19725, filed on 31 Aug 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-144096, filed on 31 Aug 1998, PENDING
DT Utility
FS APPLICATION
LREP NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 2171
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions, and methods are provided for **treatment** of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing **pyrimidine nucleotide precursors** in amounts sufficient to **treat** symptoms resulting from mitochondrial respiratory chain deficiencies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 39 OF 68 USPATFULL on STN
AN 2002:78730 USPATFULL
TI Method for **treating** inflammatory bowel disease and other forms of gastrointestinal inflammation
IN Raz, Eyal, Del Mar, CA, UNITED STATES
Rachmilewitz, Daniel, Tel Aviv, ISRAEL
PI US 2002042387 A1 20020411
US 6613751 B2 20030902
AI US 2001-791500 A1 20010222 (9)
PRAI US 2000-184256P 20000223 (60)
DT Utility
FS APPLICATION
LREP Carol L. Francis, BOZICEVIC, FIELD & FRANCIS LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA, 94025
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1759
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method for ameliorating gastrointestinal inflammation, particularly chronic gastrointestinal inflammation such as inflammatory bowel disease (IBD), in a subject. In one embodiment, the method comprises administering an immunomodulatory nucleic acid to a subject suffering from or susceptible to gastrointestinal inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 40 OF 68 USPATFULL on STN
AN 2002:72850 USPATFULL
TI Gene sequence variances in genes related to folate metabolism having utility in determining the **treatment** of disease

IN Stanton, Vincent P., JR., Belmont, MA, UNITED STATES
PI US 2002039990 A1 20020404
AI US 2000-733651 A1 20001207 (9)
RLI Continuation-in-part of Ser. No. US 2000-710768, filed on 8 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2000-696634, filed on 24 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-684359, filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-638267, filed on 14 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-596033, filed on 15 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-357743, filed on 20 Jul 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-357024, filed on 19 Jul 1999, ABANDONED
PRAI US 1998-93484P 19980720 (60)
DT Utility
FS APPLICATION
LREP ANITA L. MEIKLEJOHN, PH.D., FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 119
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 7986
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure describes the use of genetic variance information for folate transport or metabolism genes or pyrimidine transport or metabolism genes in the selection of effective methods of **treatment** of a disease or condition. The variance information is indicative of the expected response of a patient to a method of **treatment**. Methods of determining relevant variance information and additional methods of using such variance information are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 41 OF 68 USPATFULL on STN
AN 2002:9933 USPATFULL
TI Enzyme catalyzed therapeutic agents
IN Shepard, H. Michael, Rancho Santa Fe, CA, United States
Groziak, Michael P., Palo Alto, CA, United States
PA NewBiotics, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6339151 B1 20020115
AI US 1999-235961 19990122 (9)
PRAI US 1998-108634P 19981116 (60)
US 1998-76950P 19980305 (60)
US 1998-72264P 19980123 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Fonda, Kathleen Kahler; Assistant Examiner: Crane, L. E.
LREP Konski, Antoinette F., McCutchen, Brown, Doyle & Enersen LLP
CLMN Number of Claims: 9
ECL Exemplary Claim: 1,2,3,4
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 3289
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method for identifying potential therapeutic agents by contacting a target cell with a candidate therapeutic agent which is a selective substrate for an endogenous, intracellular enzyme in the cell which is enhanced in its expression as a result of selection by biologic or **chemotherapy**. This invention also provides methods and examples of molecules for selectively killing a pathological cell by contacting the cell with a prodrug that is a selective substrate for an endogenous, intracellular enzyme. The prodrug is subsequently converted to a cellular toxin. Further provided by this invention is a method for **treating** a pathology characterized by pathological, hyperproliferative cells in a subject by administering to the subject a prodrug that is a selective substrate for an endogenous, overexpressed, intracellular enzyme, and converted by the enzyme to a cellular toxin in the hyperproliferative cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 42 OF 68 USPATFULL on STN
AN 2001:226607 USPATFULL
TI **Pyrimidine nucleotide precursors** for **treatment** of systemic inflammation and inflammatory hepatitis
IN von Borstel, Reid W., Potomac, MD, United States
Bamat, Michael K., Potomac, MD, United States
Hiltbrand, Bradley M., Columbia, MD, United States
PA Pro-Neuron, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6329350 B1 20011211
AI US 1995-464939 19950605 (8)
RLI Division of Ser. No. US 1994-266897, filed on 1 Jul 1994 Continuation-in-part of Ser. No. US 1993-158799, filed on 1 Dec 1993, now abandoned Continuation-in-part of Ser. No. US 1992-987730, filed on 8 Dec 1992, now abandoned Continuation-in-part of Ser. No. US 438493, now abandoned Continuation-in-part of Ser. No. US 1987-115929, filed on 28 Oct 1987, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Owens, Jr., Howard V.
LREP Nixon & Vanderhye
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1844
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Pyrimidine nucleotide precursors** including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 43 OF 68 USPATFULL on STN
AN 2001:188806 USPATFULL
TI Enzyme catalyzed therapeutic agents
IN Shepard, H. Michael, Rancho Santa Fe, CA, United States
Groziak, Michael P., Palo Alto, CA, United States
PI US 2001034440 A1 20011025
AI US 2001-782721 A1 20010212 (9)
RLI Continuation of Ser. No. US 1999-235961, filed on 22 Jan 1999, PENDING
PRAI US 1998-72264P 19980123 (60)
US 1998-76950P 19980305 (60)
US 1998-108634P 19981116 (60)
DT Utility
FS APPLICATION
LREP BAKER & MCKENZIE, 660 HANSEN WAY, PALO ALTO, CA, 94304
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method for identifying potential therapeutic agents by contacting a target cell with a candidate therapeutic agent which is a selective substrate for an endogenous, intracellular enzyme in the cell which is enhanced in its expression as a result of selection by biologic or **chemotherapy**. This invention also provides methods and examples of molecules for selectively killing a pathological cell by contacting the cell with a prodrug that is a selective substrate for an endogenous, intracellular enzyme. The prodrug is subsequently converted to a cellular toxin. Further provided by this invention is a method for **treating** a pathology characterized by pathological, hyperproliferative cells in a subject by administering to the subject a prodrug that is a selective substrate for an endogenous, overexpressed, intracellular enzyme, and converted by the enzyme to a cellular toxin in the hyperproliferative cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 44 OF 68 USPATFULL on STN

AN 2001:165822 USPATFULL
TI **TREATMENT** OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES
IN VON BORSTEL, REID W., POTOMAC, MD, United States
BAMAT, MICHAEL K., POTOMAC, MD, United States
PI US 2001025032 A1 20010927
US 6344447 B2 20020205
AI US 1999-249790 A1 19990216 (9)
RLI Continuation of Ser. No. US 1995-472210, filed on 7 Jun 1995, GRANTED, Pat. No. US 5968914 Continuation of Ser. No. US 1993-176485, filed on 30 Dec 1993, GRANTED, Pat. No. US 5736531 Continuation-in-part of Ser. No. US 1993-61381, filed on 14 May 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-903107, filed on 25 Jun 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-724340, filed on 5 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1990-438493, filed on 26 Jun 1990, ABANDONED Continuation-in-part of Ser. No. US 1987-115929, filed on 28 Oct 1987, ABANDONED Continuation-in-part of Ser. No. US 1990-487984, filed on 5 Feb 1990, ABANDONED Continuation-in-part of Ser. No. US 1987-115923, filed on 28 Oct 1987, ABANDONED
DT Utility
FS APPLICATION
LREP NIXON & VANDERHYE, ATTY LEONARD C MITCHARD, 1100 NORTH GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA, 222014714
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2891
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention discloses compounds, compositions and methods for **treatment** and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic **chemotherapy**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 45 OF 68 USPATFULL on STN
AN 2001:139534 USPATFULL
TI Compositions and methods for **treatment** of mitochondrial diseases
IN von Borstel, Reid W., Potomac, MD, United States
PA Pro-Neuron, Inc. (U.S. corporation)
PI US 2001016576 A1 20010823
AI US 2001-838136 A1 20010420 (9)
RLI Continuation of Ser. No. US 1998-144096, filed on 31 Aug 1998, PENDING
DT Utility
FS APPLICATION
LREP Nixon & Vanderhye P.C., 8th Floor, 1100 N. Glebe Rd., Arlington, VA, 22201
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions, and methods are provided for **treatment** of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing **pyrimidine nucleotide precursors** in amounts sufficient to **treat** symptoms resulting from mitochondrial respiratory chain deficiencies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 46 OF 68 USPATFULL on STN
AN 2001:100342 USPATFULL
TI COMPOSITIONS AND METHODS FOR **TREATMENT** OF MITOCHONDRIAL DISEASES
IN VON BORSTEL, REID W., POTOMAC, MD, United States
PI US 2001005719 A1 20010628

PI US 6472378 B2 20021029
AI US 1998-144096 A1 19980831 (9)
DT Utility
FS APPLICATION
LREP NIXON & VANDERHYE, 1100 N. GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA, 22201
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions, and methods are provided for **treatment** of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing **pyrimidine nucleotide precursors** in amounts sufficient to **treat** symptoms resulting from mitochondrial respiratory chain deficiencies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 47 OF 68 USPATFULL on STN
AN 2001:86452 USPATFULL
TI Enzyme catalyzed therapeutic agents
IN Shepard, H. Michael, Rancho Santa Fe, CA, United States
PA NewBiotics, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6245750 B1 20010612
AI US 1999-235809 19990122 (9)
PRAI US 1998-72264P 19980123 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Crane, L. E.
LREP Konski, Antoinette F.Baker & McKenzie
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 3298
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method for identifying potential therapeutic agents by contacting a target cell with a candidate therapeutic agent which is a selective substrate for an endogenous, intracellular enzyme in the cell which is enhanced in its expression as a result of selection by biologic or **chemotherapy**. This invention also provides methods and examples of molecules for selectively killing a pathological cell by contacting the cell with a prodrug that is a selective substrate for an endogenous, intracellular enzyme. The prodrug is subsequently converted to a cellular toxin. Further provided by this invention is a method for **treating** a pathology characterized by pathological, hyperproliferative cells in a subject by administering to the subject a prodrug that is a selective substrate for an endogenous, overexpressed, intracellular enzyme, and converted by the enzyme to a cellular toxin in the hyperproliferative cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 48 OF 68 USPATFULL on STN
AN 2001:71533 USPATFULL
TI **Pyrimidine nucleotide precursors** for **treatment** of systemic inflammation and inflammatory hepatitis
IN von Borstel, Reid W., Potomac, MD, United States
Bamat, Michael K., Potomac, MD, United States
Hiltbrand, Bradley M., Columbia, MD, United States
PA Pro-Neuron, Inc., Gaithersburg, MD, United States (U.S. corporation)
PI US 6232298 B1 20010515
AI US 1995-479519 19950607 (8)
RLI Division of Ser. No. US 1994-266897, filed on 1 Jul 1994 Continuation-in-part of Ser. No. US 1993-158799, filed on 19 Dec 1993, now abandoned Continuation-in-part of Ser. No. US 1992-987730, filed on 8 Dec 1992, now abandoned Continuation-in-part of Ser. No. US 1990-438493, filed on 26 Jun 1990, now abandoned Continuation-in-part of Ser. No. US 1987-115929, filed on 28 Oct 1987, now abandoned
DT Utility

FS Granted
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Owens, Howard
LREP Nixon & Vanderhye
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1818
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Pyrimidine nucleotide precursors** including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 49 OF 68 USPATFULL on STN
AN 2001:36603 USPATFULL
TI Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
IN Housman, David E., Newton, MA, United States
Ledley, Fred D., Needham, MA, United States
Stanton, Jr., Vincent P., Belmont, MA, United States
PA Variagenics, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6200754 B1 20010313
AI US 1998-45054 19980319 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Schwartzman, Robert A.; Assistant Examiner: Epps, Janet L.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 3654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for the **treatment** of proliferative disorders using compounds and/or environmental conditions which result in a difference in sensitivity of targeted and non-targeted cells. Certain of the methods involve the identification and use of allele-specific inhibitors of conditionally essential genes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 50 OF 68 USPATFULL on STN
AN 2001:1466 USPATFULL
TI Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
IN Janjic, Nebojsa, Boulder, CO, United States
Gold, Larry, Boulder, CO, United States
Schmidt, Paul, Niwot, CO, United States
Vargeese, Chandra, Thornton, CO, United States
PA NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)
PI US 6168778 B1 20010102
AI US 1997-870930 19970606 (8)
RLI Continuation-in-part of Ser. No. US 1995-447169, filed on 19 May 1995, now patented, Pat. No. US 5811533 Continuation-in-part of Ser. No. US 1994-233012, filed on 25 Apr 1994, now patented, Pat. No. US 5849479 Continuation-in-part of Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 Continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned Continuation-in-part of Ser. No. US 1992-964624, filed on 21 Oct 1992, now patented, Pat. No. US 5496938 Continuation-in-part of Ser. No. US 1994-234997, filed on 28 Apr 1994, now patented, Pat. No. US 5683867
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie
LREP Swanson & Bratschun L.L.C.
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2393

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 51 OF 68 USPATFULL on STN
AN 2000:168000 USPATFULL
TI Anti-malarial composition and method of use
IN Rathod, Pradipsinh K, Wheaton, MD, United States
PA Catholic University of America, Washington, DC, United States (U.S. corporation)
PI US 6159953 20001212
AI US 1992-851103 19920316 (7)
RLI Continuation of Ser. No. US 1989-369472, filed on 21 Jun 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Wilson, James O.
LREP Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Anti-malarial compositions for prophylactic or therapeutic **treatment** of vertebrates exposed to malaria parasites are disclosed. These compositions comprise one or more pyrimidine analogue inhibitors of nucleic acid biosynthesis, e.g., 5-fluoro-orotic acid, alone or together with one or more "rescue" compounds, e.g., a normal pyrimidine base or nucleoside that can be used by the host vertebrate, but not by malaria-causing parasites, for nucleic acid biosynthesis. Also claimed are methods of prophylactic and therapeutic use of these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 52 OF 68 USPATFULL on STN
AN 2000:113937 USPATFULL
TI Carbocyclic heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
IN Magolda, Ronald Louis, Wallingford, PA, United States
Pitts, William John, Conshohocken, PA, United States
Jacobson, Irina Cipora, Boothwyn, PA, United States
Behrens, Carl Henry, Newark, DE, United States
Orwat, Michael James, Wilmington, DE, United States
Batt, Douglas Guy, Wilmington, DE, United States
PA Dupont Pharmaceuticals, Wilmington, DE, United States (U.S. corporation)
PI US 6110910 20000829
AI US 1998-195366 19981118 (9)
RLI Division of Ser. No. US 1997-820222, filed on 18 Mar 1997, now patented, Pat. No. US 5874441 which is a division of Ser. No. US 1995-411251, filed on 27 Mar 1995, now patented, Pat. No. US 5639759 which is a division of Ser. No. US 1993-114712, filed on 31 Aug 1993, now patented, Pat. No. US 5428040
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Truong, Tamthom N.
LREP Dolan, Peter L.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2434

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the **treatment** and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 53 OF 68 USPATFULL on STN
AN 2000:53937 USPATFULL
TI Stabilized external guide sequences
IN George, Shaji T., New York, NY, United States
Ma, Michael, New York, NY, United States
Werner, Martina, New York, NY, United States
Pace, Umberto, Riverdale, NY, United States
Goldberg, Allan R., New York, NY, United States
PA Yale University, New Haven, CT, United States (U.S. corporation)
PI US 6057153 20000502
AI US 1997-892747 19970714 (8)
RLI Continuation-in-part of Ser. No. US 1995-372556, filed on 13 Jan 1995, now patented, Pat. No. US 5683873 And Ser. No. WO 1996-US513, filed on 19 Jan 1996
DT Utility
FS Granted
EXNAM Primary Examiner: Brusca, John S.; Assistant Examiner: Sandals, William
LREP Arnall Golden & Gregory, LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 38 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 3536
AB Modified external guide sequence (EGS) molecules that mediate cleavage of specific target RNAs have been constructed. The modified molecules are external guide sequence molecules for RNAse P which are designed to specifically bind to and promote RNAse P-mediated cleavage of target RNA molecules and to have enhanced nuclease resistance. Specific regions are modified to achieve enhanced stability while maintaining RNAse P activity. Modified external guide sequence molecules suitable for use in the **treatment** of hepatitis B viral infections have been constructed.

L8 ANSWER 54 OF 68 USPATFULL on STN
AN 2000:47355 USPATFULL
TI Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
IN Janjic, Nebojsa, 6973 Carter Trail, Boulder, CO, United States 80301
Gold, Larry, 1033 Fifth St., Boulder, CO, United States 80302
Schmidt, Paul, P.O. Box 1125, Niwot, CO, United States 80544
Vargeese, Chandra, 5295 E. 17th Ave., Thornton, CO, United States 80233
PI US 6051698 20000418
AI US 1997-897351 19970721 (8)
RLI Continuation-in-part of Ser. No. US 1997-870930, filed on 6 Jun 1997
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 3496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention

further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 55 OF 68 USPATFULL on STN
AN 1999:128530 USPATFULL
TI **Treatment** of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
IN von Borstel, Reid, Potomac, MD, United States
Bamat, Michael K., Potomac, MD, United States
PA Pro-Neuron, Inc., Rockville, MD, United States (U.S. corporation)
PI US 5968914 19991019
AI US 1995-472210 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1993-176485, filed on 30 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-61381, filed on 14 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-903107, filed on 25 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-724340, filed on 5 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-438493, filed on 26 Jun 1990, now abandoned And Ser. No. US 1990-487984, filed on 5 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1987-115923, filed on 28 Oct 1987, now abandoned , said Ser. No. US 438493 which is a continuation-in-part of Ser. No. US 1987-115929, filed on 28 Oct 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kunz, Gary L.
LREP Nixon & Vanderhye
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3065
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention discloses compounds, compositions and methods for **treatment** and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic **chemotherapy**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 56 OF 68 USPATFULL on STN
AN 1999:24659 USPATFULL
TI Carbocyclic and hetertocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
IN Magolda, Ronald Louis, Wallingford, PA, United States
Pitts, William John, Conshohocken, PA, United States
Jacobson, Irina Cipora, Boothwyn, PA, United States
Behrens, Carl Henry, Newark, DE, United States
Orwat, Michael James, Wilmington, DE, United States
Batt, Douglas Guy, Wilmington, DE, United States
PA DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)
PI US 5874441 19990223
AI US 1997-820222 19970318 (8)
RLI Division of Ser. No. US 1995-411251, filed on 27 Mar 1995, now patented, Pat. No. US 5639759 which is a division of Ser. No. US 1993-114712, filed on 31 Aug 1993, now patented, Pat. No. US 5428040
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Ngo, Tamthom T.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions

comprising such compounds, and to methods of using such compounds for the **treatment** and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 57 OF 68 USPATFULL on STN
AN 1998:151107 USPATFULL
TI Synthetic triple helix-forming compound **precursors**
IN Gold, Barry I., Plattsmouth, NE, United States
PA University of Nebraska Board of Regents, Omaha, NE, United States (U.S. corporation)
PI US 5844110 19981201
AI US 1995-384324 19950201 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Crane, L. Eric
LREP Dann, Dorfman, Herrel and Skillman
CLMN Number of Claims: 6
ECL Exemplary Claim: 1,4
DRWN 20 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 2108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses novel monomeric compositions which are substituted quinoline- or quinazoline-based structures capable of hydrogen bonding specifically with interstrand purine-pyrimidine base pairs in a double-stranded Watson-Crick DNA molecule. Furthermore, the novel monomeric compounds of the present invention are capable of being assembled in specific sequences into oligomers capable of binding with sequence specificity to duplex DNA via a triple helix motif.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 58 OF 68 USPATFULL on STN
AN 1998:36739 USPATFULL
TI Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
IN von Borstel, Reid W., Potomac, MD, United States
Bamat, Michael K., Potomac, MD, United States
PA Pro-Neuron, Inc., Rockville, MD, United States (U.S. corporation)
PI US 5736531 19980407
AI US 1993-176485 19931230 (8)
RLI Continuation-in-part of Ser. No. US 1993-61381, filed on 14 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-903107, filed on 25 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-724340, filed on 5 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-438493, filed on 27 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-115929, filed on 27 Oct 1987, now abandoned , said Ser. No. US -724340 which is a continuation-in-part of Ser. No. US 1990-487984, filed on 5 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1987-115923, filed on 28 Oct 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kunz, Gary L.
LREP Nixon & Vanderhye
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2580
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention discloses compounds, compositions and methods for **treatment** and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic **chemotherapy**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 59 OF 68 USPATFULL on STN
AN 97:109880 USPATFULL
TI Acylated pyrimidine nucleosides for **treatment** of systemic inflammation and inflammatory hepatitis
IN von Borstel, Reid W., Potomac, MD, United States
Bamat, Michael K., Potomac, MD, United States
Hiltbrand, Bradley M., Columbia, MD, United States
PA Pro-Neuron, Inc., Rockville, MD, United States (U.S. corporation)
PI US 5691320 19971125
AI US 1995-465454 19950605 (8)
RLI Division of Ser. No. US 1994-266897, filed on 1 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-158799, filed on 1 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-987730, filed on 8 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-438493, filed on 26 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1987-115929, filed on 28 Oct 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kunz, Gary L.
LREP Nixon & Vanderhye P.C.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Pyrimidine nucleotide precursors** including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 60 OF 68 USPATFULL on STN
AN 97:52006 USPATFULL
TI Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
IN Magolda, Ronald Louis, Wallingford, PA, United States
Pitts, William John, Conshohocken, PA, United States
Jacobson, Irina Cipora, Boothwyn, PA, United States
Behrens, Carl Henry, Newark, DE, United States
Orwat, Michael James, Wilmington, DE, United States
Batt, Douglas Guy, Wilmington, DE, United States
PA The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)
PI US 5639759 19970617
AI US 1995-411251 19950327 (8)
RLI Division of Ser. No. US 1993-114712, filed on 31 Aug 1993, now patented, Pat. No. US 5428040
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Wong, King Lit
LREP Ferguson, Blair Q.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2583
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the **treatment** and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 61 OF 68 USPATFULL on STN
AN 97:27151 USPATFULL
TI Antiparasitic oligonucleotides active against drug resistant malaria
IN Rapaport, Eliezer, Belmont, MA, United States
Zamecnik, Paul C., Shrewbury, MA, United States
PA Worcester Foundation for Biomedical Research, Inc., Worcester, MA, United States (U.S. corporation)
PI US 5616564 19970401
AI US 1994-178450 19940107 (8)
RLI Continuation of Ser. No. US 1991-815393, filed on 31 Dec 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Rories, Charles C. P.
LREP Greenfield, Michael S.McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 44
ECL Exemplary Claim: 11
DRWN No Drawings
LN.CNT 856
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and materials for antisense oligonucleotide therapy against active pathogenic infection by drug resistant or drug sensitive pathogens, including Plasmodium falciparum.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 62 OF 68 USPATFULL on STN
AN 95:58143 USPATFULL
TI Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
IN Magolda, Ronald L., Wallingford, PA, United States
Pitts, William J., Conshohocken, PA, United States
Jacobson, Irina C., Boothwyn, PA, United States
Behrens, Carl H., Newark, DE, United States
Orwat, Michael J., Wilmington, DE, United States
Batt, Douglas G., Wilmington, DE, United States
PA The Du Pont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)
PI US 5428040 19950627
AI US 1993-114712 19930831 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Hydorn, Michael B.
LREP Ferguson, Blair Q.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the **treatment** and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 63 OF 68 USPAT2 on STN
AN 2002:164677 USPAT2
TI Immunomodulatory polynucleotides in **treatment** of an infection by an intracellular pathogen
IN Raz, Eyal, Del Mar, CA, United States
Kornbluth, Richard, La Jolla, CA, United States
Catanzaro, Antonio, San Diego, CA, United States
Hayashi, Tomoko, San Diego, CA, United States
Carson, Dennis, Del Mar, CA, United States

PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
The United States of America as represented by the Department of Veteran Affairs, Washington, DC, United States (U.S. corporation)
PI US 6552006 B2 20030422
AI US 2001-774403 20010130 (9)
PRAI US 2000-179353P 20000131 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Sullivan, Daniel M.
LREP Francis, Carol L., Borden, Paula A., Bozicevic, Field & Francis, LLP
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 22 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 2193
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features methods for **treatment** or prevention of infection by intracellular pathogens (e.g., Mycobacterium species) by administration of an immunomodulatory nucleic acid molecule. In one embodiment, immunomodulatory nucleic acid molecule are administered in combination with another anti-pathogenic agent to provide a synergistic anti-pathogenic effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 64 OF 68 USPAT2 on STN
AN 2002:78730 USPAT2
TI Method for **treating** inflammatory bowel disease and other forms of gastrointestinal inflammation
IN Raz, Eyal, Del Mar, CA, United States
Rachmilewitz, Daniel, Tel Aviv, ISRAEL
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
Tel Aviv Sourasky Medical Center, Tel Aviv, ISRAEL (non-U.S. corporation)
PI US 6613751 B2 20030902
AI US 2001-791500 20010222 (9)
PRAI US 2000-184256P 20000223 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wehbe, Anne M.; Assistant Examiner: Li, Janice
LREP Borden, Paula A., Francis, Carol L., Bozicevic, Field & Francis, LLP
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 43 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 1802
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method for ameliorating gastrointestinal inflammation, particularly chronic gastrointestinal inflammation such as inflammatory bowel disease (IBD), in a subject. In one embodiment, the method comprises administering an immunomodulatory nucleic acid to a subject suffering from or susceptible to gastrointestinal inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 65 OF 68 USPAT2 on STN
AN 2001:165822 USPAT2
TI **Treatment** of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
IN von Borstel, Reid W., Potomac, MD, United States
Bamat, Michael K., Potomac, MD, United States
PA Pro-Neuron, Inc., Gaithersburg, MD, United States (U.S. corporation)
PI US 6344447 B2 20020205
AI US 1999-249790 19990216 (9)
RLI Continuation of Ser. No. US 1995-472210, filed on 7 Jun 1995, now patented, Pat. No. US 5968914
DT Utility
FS GRANTED
EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Owens, Howard V.
LREP Nixon & Vanderhye

CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2861
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention discloses compounds, compositions and methods for **treatment** and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic **chemotherapy**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 66 OF 68 USPAT2 on STN
AN 2001:100342 USPAT2
TI Compositions and methods for **treatment** of mitochondrial diseases
IN von Borstel, Reid W., Potomac, MD, United States
PA Pro-Neuron, Inc., Gaithersburg, MD, United States (U.S. corporation)
PI US 6472378 B2 20021029
AI US 1998-144096 19980831 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Schnizer, Richard
LREP Nixon & Vanderhye
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions, and methods are provided for **treatment** of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing **pyrimidine nucleotide precursors** in amounts sufficient to **treat** symptoms resulting from mitochondrial respiratory chain deficiencies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 67 OF 68 WPINDEX COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2002-556435 [59] WPINDEX
CR 2000-246628 [21]
DNC C2002-157730
TI **Treatment** of pathophysiological consequences of mitochondrial respiratory chain dysfunction, in congenital mitochondrial and neurodegenerative diseases, comprises the administration of a **pyrimidine nucleotide precursor**.
DC B03
IN SAYDOFF, J A; VON BORSTEL, R W
PA (SAYD-I) SAYDOFF J A; (VBOR-I) VON BORSTEL R W; (WELL-N) WELLSTAT THERAPEUTICS CORP
CYC 101
PI US 2002049182 A1 20020425 (200259)* 39
WO 2003015516 A1 20030227 (200316) EN
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
EP 1416795 A1 20040512 (200431) EN
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR
ADT US 2002049182 A1 CIP of US 1998-144096 19980831, CIP of WO 1999-US19725 19990831, CIP of US 2001-763955 20010228, US 2001-930494 20010816; WO 2003015516 A1 WO 2002-US25831 20020814; EP 1416795 A1 EP 2002-759363 20020814, WO 2002-US25831 20020814
FDT EP 1416795 A1 Based on WO 2003015516

PRAI US 2001-930494 20010816; US 1998-144096 19980831;
WO 1999-US19725 19990831; US 2001-763955 20010228
AN 2002-556435 [59] WPINDEX
CR 2000-246628 [21]
AB US2002049182 A UPAB: 20040514
NOVELTY - A method for **treating** pathophysiological consequences of mitochondrial respiratory chain dysfunction comprises administration of a **pyrimidine nucleotide precursor**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:

(1) a method for reducing **side effects** of cytotoxic cancer **chemotherapy** comprising administration of a **pyrimidine nucleotide precursor**;

(2) a method for diagnosing mitochondrial disease comprising administration of a **pyrimidine nucleotide precursor** and assessing clinical improvement;

(3) the compounds 2',3',5'-tri-O-pyruvuluridine, 2',3'-di-O-pyruvyluridine, 2',5'-di-O-pyruvyluridine, 3',5'-di-O-pyruvyluridine, 2'-O-pyruvyluridine, 3'-O-pyruvyluridine and 5'-O-pyruvyluridine;

(4) compositions comprising a **pyrimidine nucleotide precursor** or a salt and pyruvic acid or a salt or ester; and

(5) compositions comprising a **pyrimidine nucleotide precursor** and creatine.

ACTIVITY - Nootropic; Neuroprotective; Anti-parkinsonian; Anti-convulsant; Tranquilizer; Anti-migraine.

MECHANISM OF ACTION - None given in the source material.

USE - The method is useful for **treating** pathophysiological consequences of mitochondrial respiratory chain dysfunction, especially caused by mutation, deletion or rearrangement of mitochondrial DNA, defective nuclear-encoded protein components of the mitochondrial respiratory chain, aging, administration of cytotoxic cancer **chemotherapy** agents, deficit in mitochondrial Complex I activity, deficit in mitochondrial Complex II activity, deficit in mitochondrial Complex III activity, deficit in mitochondrial Complex IV activity or deficit in mitochondrial Complex V activity.

This method is useful for **treating** congenital mitochondrial disease, (especially MELAS, LHON, MERRF, MNGIE, NARP, PEO, Leigh's disease and Keams-Sayres Syndrome), neurodegenerative diseases (especially Alzheimer's disease, Parkinson's disease and Huntington's disease), neuromuscular degenerative disease (especially muscular dystrophy, myotonic dystrophy, chronic fatigue syndrome and Friedreich's ataxia), developmental delay in cognitive, motor, language or executive function or social skills (especially pervasive developmental delay, PDD-NOS, attention deficit/hyperactivity disorder, Rett's syndrome and autism), epilepsy, peripheral neuropathy, optic neuropathy, autonomic neuropathy, neurogenic bowel dysfunction, sensorineural deafness, neurogenic bladder dysfunction, migraine, ataxia, renal tubular acidosis, dilating cardiomyopathy, steatohepatitis, hepatic failure and lactic acidemia.

Also, this method is useful for preventing death or functional decline of post-mitotic cells due to mitochondrial respiratory chain dysfunction, especially neurons, skeletal muscle cells and cardiomyocytes. It can be used for reducing **side effects** of cytotoxic cancer **chemotherapy**.

Dwg.0/16

L8 ANSWER 68 OF 68 WPINDEX COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2000-246628 [21] WPINDEX
CR 2002-556435 [59]
DNC C2000-074669
TI New method for **treating** or preventing pathophysiological consequences of mitochondrial respiratory chain dysfunction in mammals comprising administration of a **pyrimidine nucleotide**..
DC B03
IN VON BORSTEL, R W
PA (PRON-N) PRO-NEURON INC; (VBOR-I) VON BORSTEL R W
CYC 87
PI WO 2000011952 A1 20000309 (200021)* EN 58
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU

LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AU 9960219 A 20000321 (200031)
BR 9913319 A 20010522 (200132)
EP 1109453 A1 20010627 (200137) EN
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
US 2001005719 A1 20010628 (200138)
US 2001016576 A1 20010823 (200151)
KR 2001085746 A 20010907 (200218)
CN 1328417 A 20011226 (200227)
HU 2001003255 A2 20020429 (200238)
MX 2001002179 A1 20010801 (200238)
JP 2002523434 W 20020730 (200264) 65
ZA 2001001565 A 20020731 (200271) 74
US 6472378 B2 20021029 (200274)
AU 753203 B 20021010 (200279)
AU 2002313992 A1 20030403 (200432)#

ADT WO 2000011952 A1 WO 1999-US19725 19990831; AU 9960219 A AU 1999-60219 19990831; BR 9913319 A BR 1999-13319 19990831, WO 1999-US19725 19990831; EP 1109453 A1 EP 1999-968207 19990831, WO 1999-US19725 19990831; US 2001005719 A1 US 1998-144096 19980831; US 2001016576 A1 Cont of US 1998-144096 19980831, US 2001-838136 20010420; KR 2001085746 A KR 2001-702678 20010228; CN 1328417 A CN 1999-812541 19990831; HU 2001003255 A2 WO 1999-US19725 19990831, HU 2001-3255 19990831; MX 2001002179 A1 MX 2001-2179 20010228; JP 2002523434 W WO 1999-US19725 19990831, JP 2000-567085 19990831; ZA 2001001565 A ZA 2001-1565 20010226; US 6472378 B2 US 1998-144096 19980831; AU 753203 B AU 1999-60219 19990831; AU 2002313992 A1 Div ex AU 1999-60219 19990831, AU 2002-313992 20021204

FDT AU 9960219 A Based on WO 2000011952; BR 9913319 A Based on WO 2000011952; EP 1109453 A1 Based on WO 2000011952; HU 2001003255 A2 Based on WO 2000011952; JP 2002523434 W Based on WO 2000011952; AU 753203 B Previous Publ. AU 9960219, Based on WO 2000011952

PRAI US 1998-144096 19980831; US 2001-838136 20010420; AU 2002-313992 20021204

AN 2000-246628 [21] WPINDEX

CR 2002-556435 [59]

AB WO 200011952 A UPAB: 20040520

NOVELTY - A new method for **treating** or preventing pathophysiological consequences of mitochondrial respiratory chain dysfunction in mammals comprises administration of a **pyrimidine nucleotide**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a new pyrimidine nucleoside selected from 2',3',5'-tri-O-pyruvyluridine, 2',3'-di-O-pyruvyluridine, 2',5'-di-O-pyruvyluridine, 3',5'-di-O-pyruvyluridine, 2'-O-pyruvyluridine, 3'-O-pyruvyluridine or 5'-O-pyruvyluridine; and

(2) a composition comprising a **pyrimidine nucleotide precursor** or its salt, and pyruvic acid, its salt or ester.

ACTIVITY - Nootropic; neuroprotective; antiparkinsonian; anticonvulsant; antimigraine; tranquilizer; autonomic; gastrointestinal; ophthalmological. A 2 year-old girl with Leigh's Syndrome (subacute necrotizing encephalopathy) associated with severe Complex I deficiency displayed renal tubular acidosis requiring intravenous administration of sodium bicarbonate (25 mEq/day). Within several hours of beginning intragastric **treatment** with triacetyluridine (0.1 g./kg./day), her renal tubular acidosis resolved and supplementary bicarbonate was no longer required to normalize blood pH. Triacetyluridine also resulted in rapid normalization of elevated circulating amino acid concentrations and maintained lactic acid at low levels after withdrawal of dichloroacetate **treatment** which was previously required to prevent lactic acidosis.

MECHANISM OF ACTION - The **pyrimidine nucleotide** is an antagonist of the consequences of mitochondrial respiratory chain dysfunction.

USE - The **pyrimidine nucleotide** is useful for **treating** of preventing respiratory chain dysfunction caused by a mutation, deletion or rearrangement of mitochondrial DNA, by defective nuclear-encoded protein components of the mitochondrial respiratory chain,

by aging or by administration of cytotoxic cancer **chemotherapy** agents. The respiratory chain dysfunction is a deficit in mitochondrial Complex I, II, III, IV or V activity. The pathophysiological consequence of mitochondrial respiratory chain dysfunction is a congenital mitochondrial disease, a neurodegenerative disease, a neuromuscular degenerative disease, developmental delay in cognitive, motor, language, executive function or social skills, epilepsy, peripheral-neuropathy, optic neuropathy, autonomic neuropathy, neurogenic bowel dysfunction, sensoneural deafness, neurogenic bladder dysfunction, migraine or ataxia or renal tubular acidosis, dilating cardiomyopathy, steatohepatitis, hepatic failure or lactic acidemia. The congenital mitochondrial disease is selected from MELAS, LHON, MERRF, MNGIE, NARP, PEO, Leigh's disease and Kearns-Sayres Syndrome. The neurodegenerative disorder is Alzheimer's Disease, Parkinson's disease, Huntington's Disease or age-related decline in cognitive function. The neuromuscular degenerative disease is selected from muscular dystrophy, myotonic dystrophy, chronic fatigue syndrome and Friedrich's Ataxia. The developmental delay is pervasive developmental delay or PDD-NOS, Attention Deficit/Hyperactivity Disorder, Rett's syndrome or autism. **Pyrimidine nucleotide precursor** prevents also the death or functional decline of post-mitotic cells in mammals due to mitochondrial respiratory chain dysfunction. The post-mitotic cells are neurons, skeletal muscle cells or cardiomyocytes. **Pyrimidine nucleotide precursor** reduces also the **side effects** of cytotoxic cancer **chemotherapy** agents, where the **chemotherapy** agent is not a pyrimidine nucleoside analog. The **side effects** are particularly peripheral neuropathy, **chemotherapy**-induced menopause, **chemotherapy**-associated fatigue or depressed appetite. Mitochondrial disease in mammals may be diagnosed by administration of a **pyrimidine nucleotide precursor** and assessment of clinical improvement in signs and symptoms (all claimed).
Dwg.0/0

=> dis hist

(FILE 'HOME' ENTERED AT 09:51:50 ON 04 JUN 2004)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, DISSABS, EMA, IFIPAT, JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPIFV, WPINDEX, WTEXTILES' ENTERED AT 09:52:02 ON 04 JUN 2004

```
L1          6860 S PYRIMIDINE(W)NUCLEOTIDE
L2           810 S L1 AND SIDE(W)EFFECT
L3           119 S L2 AND CHEMOTHERAPY
L4           117 S L3 AND TREAT?
L5           873 S L1 AND PRECURSOR
L6           228 S L5 AND SIDE(W)EFFECT
L7            68 S L6 AND CHEMOTHERAPY
L8            68 S L7 AND TREAT?
```

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	209.25	209.46

STN INTERNATIONAL LOGOFF AT 10:00:33 ON 04 JUN 2004